These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 30206174)
21. Achieving cross-reactivity with pan-ebolavirus antibodies. King LB; Milligan JC; West BR; Schendel SL; Ollmann Saphire E Curr Opin Virol; 2019 Feb; 34():140-148. PubMed ID: 30884329 [TBL] [Abstract][Full Text] [Related]
22. Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease. Luczkowiak J; Lasala F; Mora-Rillo M; Arribas JR; Delgado R J Infect Dis; 2018 Nov; 218(suppl_5):S574-S581. PubMed ID: 29939289 [TBL] [Abstract][Full Text] [Related]
23. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939 [TBL] [Abstract][Full Text] [Related]
24. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755 [TBL] [Abstract][Full Text] [Related]
25. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP. Reynard O; Volchkov VE J Infect Dis; 2015 Oct; 212 Suppl 2():S372-8. PubMed ID: 26232760 [TBL] [Abstract][Full Text] [Related]
26. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Bornholdt ZA; Herbert AS; Mire CE; He S; Cross RW; Wec AZ; Abelson DM; Geisbert JB; James RM; Rahim MN; Zhu W; Borisevich V; Banadyga L; Gunn BM; Agans KN; Wirchnianski AS; Goodwin E; Tierney K; Shestowsky WS; Bohorov O; Bohorova N; Velasco J; Ailor E; Kim D; Pauly MH; Whaley KJ; Alter G; Walker LM; Chandran K; Zeitlin L; Qiu X; Geisbert TW; Dye JM Cell Host Microbe; 2019 Jan; 25(1):49-58.e5. PubMed ID: 30629918 [TBL] [Abstract][Full Text] [Related]
27. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862 [TBL] [Abstract][Full Text] [Related]
28. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. Nyakatura EK; Zak SE; Wec AZ; Hofmann D; Shulenin S; Bakken RR; Aman MJ; Chandran K; Dye JM; Lai JR J Biol Chem; 2018 Apr; 293(16):6201-6211. PubMed ID: 29500195 [TBL] [Abstract][Full Text] [Related]
29. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop. Mire CE; Geisbert TW Trends Mol Med; 2017 Aug; 23(8):669-671. PubMed ID: 28697885 [TBL] [Abstract][Full Text] [Related]
30. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Flyak AI; Kuzmina N; Murin CD; Bryan C; Davidson E; Gilchuk P; Gulka CP; Ilinykh PA; Shen X; Huang K; Ramanathan P; Turner H; Fusco ML; Lampley R; Kose N; King H; Sapparapu G; Doranz BJ; Ksiazek TG; Wright DW; Saphire EO; Ward AB; Bukreyev A; Crowe JE Nat Microbiol; 2018 Jun; 3(6):670-677. PubMed ID: 29736037 [TBL] [Abstract][Full Text] [Related]
31. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Milligan JC; Davis CW; Yu X; Ilinykh PA; Huang K; Halfmann PJ; Cross RW; Borisevich V; Agans KN; Geisbert JB; Chennareddy C; Goff AJ; Piper AE; Hui S; Shaffer KCL; Buck T; Heinrich ML; Branco LM; Crozier I; Holbrook MR; Kuhn JH; Kawaoka Y; Glass PJ; Bukreyev A; Geisbert TW; Worwa G; Ahmed R; Saphire EO Cell; 2022 Mar; 185(6):995-1007.e18. PubMed ID: 35303429 [TBL] [Abstract][Full Text] [Related]
32. Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies. Ilinykh PA; Graber J; Kuzmina NA; Huang K; Ksiazek TG; Crowe JE; Bukreyev A J Infect Dis; 2018 Nov; 218(suppl_5):S418-S422. PubMed ID: 30060231 [TBL] [Abstract][Full Text] [Related]
33. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Lee JE; Saphire EO Curr Opin Struct Biol; 2009 Aug; 19(4):408-17. PubMed ID: 19559599 [TBL] [Abstract][Full Text] [Related]
34. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope. Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021 [TBL] [Abstract][Full Text] [Related]
35. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263 [TBL] [Abstract][Full Text] [Related]